Translation of BD1's technology into a commercial test kit could be tricky but the commercial potential of such a successful blood test for ovarian cancer would be stupendous. If established for routine screening, ultimately the gross annual income from such a test would exceed the present market cap. IF ( I emphasise '"if" ) the adaptation to a commercial kit comes off, I would hope that BD1 seeks a royalty arrangement or partnership rather than accept a complete TO offer or one off sale of this test. There is further promise in the pipeline with other BD1 projects.
Sense a Cap Raising, page-12
Add IIQ (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
47.5¢ |
Change
-0.005(1.04%) |
Mkt cap ! $53.53M | |||
| Open | High | Low | Value | Volume |
| 48.0¢ | 48.0¢ | 47.5¢ | $29.99K | 62.82K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 35189 | 47.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 49.0¢ | 1700 | 1 |
View Market Depth
| Last trade - 13.01pm 03/10/2024 (20 minute delay) ? |
| IIQ (ASX) Chart |